PURPOSE The role of axillary conservation after neoadjuvant chemotherapy (NACT) is
debatable. We routinely carry out complete axillary lymph node dissection (ALND). This …

Background Axillary lymph node dissection (ALND) is increasingly omitted for breast cancer
patients with pathologic nodal disease after neoadjuvant chemotherapy (NAC). This study …

Introduction The benefits that neoadjuvant chemotherapy (NAC) provides in treating patients
with breast cancer are well known. However, its effects on axillary lymph nodes and lymph …

Highlights The study aimed to determine the proportion of breast cancer patients indicated
for ALND after NAC who later show ypN0, and to identify the reasons that led to ALND which …

Background Neoadjuvant chemotherapy (NAC) may downstage axillary disease in node-
positive breast cancer. Several clinical trials have shown that sentinel lymph node (SLN) …

Background The management of clinically node-positive breast cancer after neoadjuvant
chemotherapy (NAC) has progressed with the potential to avoid the morbidity of axillary …

Importance Increasing evidence supports the oncologic safety of de-escalating axillary
surgery for patients with breast cancer after neoadjuvant chemotherapy (NAC). Objective To …

Background: With the recent advances in breast cancer management in the neo-adjuvant
chemotherapy (NACT) setting the rates of pathological complete response (pCR) in the …

Background Axillary management after neoadjuvant chemotherapy (NAC) is evolving but
axillary lymph node dissection (ALND) remains the standard of care for patients with …

Background There is no consensus on axillary management after neoadjuvant therapy
(NAT) in patients with clinically node-positive (cN+) breast cancer. To investigate current …